A single infusion of an experimental gene-editing therapy kept cholesterol and triglyceride levels sharply lower a full year after treatment, Cleveland Clinic researchers reported last month, an early signal that one-time CRISPR-based editing might eventually compete with daily pills or repeat injections for stubborn lipid disorders. The one-year results, presented at the European Society of Cardiology's annual congress and published in the New England Journal of Medicine, extend a Phase 1a trial that first reported safety data in late 2025.
The trial enrolled just 15 adults with uncontrolled high cholesterol, moderate-to-severe high triglycerides or mixed dyslipidemia, all of whom were already on the maximum tolerated doses of standard lipid-lowering drugs. Each received a single intravenous infusion of the therapy, called CTX310, at escalating doses between 0.1 and 0.8 milligrams per kilogram of body weight. At the highest dose, researchers measured average one-year reductions of 78.6% in ANGPTL3 protein, 52.5% in LDL ("bad") cholesterol, 47.8% in triglycerides and 37.2% in apolipoprotein B, with no dose-limiting toxic effects or serious treatment-related adverse events recorded.
CTX310 uses CRISPR-Cas9, delivered inside a lipid nanoparticle, to disable the ANGPTL3 gene in liver cells. ANGPTL3 normally makes a protein that blocks two enzymes involved in clearing fat from the bloodstream; people born with naturally occurring loss-of-function mutations in the gene have lifelong low LDL and triglyceride levels and reduced heart-disease risk, with no apparent downside. Drugmakers have spent years mimicking that effect with antibodies and RNA-silencing drugs requiring repeat dosing; a one-time edit, if it holds up, would in principle only need to be done once.
A tiny, industry-funded, open-label trial
Cleveland Clinic cardiologist Luke Laffin, M.D., the study's co-first author, said the persistence of the effect was the most notable part of the update.
The durability of the lipid-lowering effect was impressive.
Luke Laffin, M.D., Cleveland Clinic cardiologist
Steven Nissen, M.D., the Cleveland Clinic's chief academic officer for its Heart, Vascular & Thoracic Institute and the trial's corresponding author, noted that measured levels stayed essentially flat across the full year, which he said suggested the edit itself was holding rather than wearing off. Still, this remains a small, open-label, uncontrolled study funded by CTX310's maker, CRISPR Therapeutics AG, with no placebo group, a design that cannot rule out other explanations even though the underlying biology is well understood from human genetics. The FDA has asked for 15 years of follow-up monitoring, standard for gene-editing therapies, partly because the liver replaces roughly a fifth of its cells annually and because of a still-theoretical concern about edited cells and long-term cancer risk.
Cleveland Clinic said a Phase 1b trial is expected to begin soon, giving all participants the same higher dose and focusing on narrower groups of patients rather than the mixed population enrolled so far. Any path to approval would still require larger, randomized, placebo-controlled trials measuring actual heart attacks and strokes, not just cholesterol numbers, a process likely to take years. Outside cardiologists have called the data encouraging but preliminary, a caution echoed in Cleveland Clinic's own announcement, a fuller dosing breakdown in its physician-facing summary, and independent trade coverage of the update.
